New antibody drug added to Oxford University trial of Covid-19 treatments

Regeneron’s experimental drug REGN-COV2 to be added to UK’s Recovery trial

The Oxford-based Recovery trial which proved that steroids saved the lives of some Covid patients will now take on a promising but far more expensive new antibody combination treatment, it has been announced.

A cohort of patients joining the trial in most NHS acute hospitals will be randomly allocated to Regeneron’s experimental drug, called REGN-COV2. The drug is a combination of two human neutralising antibodies against the virus. The company previously developed a similar antibody drug against Ebola.

Continue reading…